Ysse Technologies
Builds a technology platform that harnesses the biology of the real nose and merges it with cutting-edge nanotechnology.
| Date | Investors | Amount | Round |
|---|---|---|---|
| - | investor | €0.0 | round |
| investor | €0.0 | round | |
| investor | €0.0 | round | |
| investor | €0.0 | round | |
| investor investor investor investor | €0.0 | round | |
| investor | €0.0 | round | |
| investor | €0.0 | round | |
| investor | €0.0 | round | |
| N/A | €0.0 | round | |
| N/A | N/A | Series A | |
| Total Funding | 000k | ||
| USD | 2021 |
|---|---|
| Revenues | 0000 |
| EBITDA | 0000 |
| Profit | 0000 |
| EV | 0000 |
| EV / revenue | 00.0x |
| EV / EBITDA | 00.0x |
| R&D budget | 0000 |
Source: Dealroom estimates
Related Content
Ysse Technologies, formerly known as MouSensor, is a biotechnology company developing a platform to digitize the sense of smell. Founded in February 2016 by Dr. Charlotte D'Hulst and Professor Paul Feinstein as a spinout from The City University of New York (CUNY), the company is headquartered in New York City. The venture originated from technology developed at the Feinstein Lab for Neurogenetics at Hunter College, where Dr. D'Hulst was a postdoctoral researcher and Prof. Feinstein is a world expert in the molecular biology of olfaction.
The company's core technology merges the biology of the nose with nanotechnology to create a "nose-on-a-chip." It utilizes a patented genetic platform to engineer mice, called "MouSensors," whose noses can produce large quantities of any mammalian odorant receptor. This process effectively turns the mouse nose into a bioreactor for these receptors, which can then be integrated onto a silicon chip for electronic analysis. The objective is to create the first-ever digital database of scent, a field the company terms "Odoromics."
Ysse Technologies aims to serve multiple industries. In the fragrance and flavor sector, the platform offers an objective method for measuring and engineering new scents. A significant area of focus is medical diagnostics, where the technology can be used to identify unique odor signatures associated with diseases like Parkinson's. The company has partnered with The Michael J. Fox Foundation for Parkinson's Research to explore this application. Further applications include the detection of explosives and other contraband.
The company's business model involves leveraging this platform to disrupt markets that rely on smell. To advance its technology, Ysse Technologies has collaborated with the nano-electronics research center imec in Belgium, a partnership supported by a grant from Flanders Innovation & Entrepreneurship (VLAIO). In September 2018, the company closed a $3.3 million seed funding round co-led by imec.xpand and Alexandria Venture Investments, with participation from New York Ventures.
Keywords: biosensing, olfaction, nanotechnology, odoromics, nose-on-a-chip, medical diagnostics, fragrance, flavor, genetic platform, chemosignatures